According to the FDA and EMA technical specification for [18F]flortaucipir, this compound is granted to estimate the density and distribution of aggregated tau NFTs for adult patients with cognitive impairment who are being evaluated for AD [18]. The gene discussed is MAPT; the disease is Cognitive impairment.